Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE PAOLI-BRUNO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1982601159
CMS profile
419826
Location
MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$120.40

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $120.40 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan Inc. $120.40 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE PAOLI-BRUNO

NPI 1982601159 · CMS profile ID 419826

Allopathic & Osteopathic Physicians / Family Medicine

MEDLEY, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JORGE PAOLI-BRUNO, NPI 1982601159, CMS profile ID 419826, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1982601159?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $120.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan Inc. $120.4010/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670916157 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $120.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $961,612.31 249
PY2024 Recipient $4,214.80 1
PY2024 Principal investigator $2,148,310.31 277
PY2023 Principal investigator $1,000,560.67 172
PY2022 Recipient $253.00 2
PY2022 Principal investigator $730,831.67 34
PY2021 Recipient $1,654.33 2
PY2021 Principal investigator $437,077.46 64
PY2020 Recipient $2,885.98 3
PY2020 Principal investigator $359,635.45 60
PY2019 Principal investigator $605,972.33 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $10,975.20 12/24/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832560597
Principal investigator 1 PFIZER INC. $34,034.21 12/24/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832561309
Principal investigator 1 PFIZER INC. $20,104.96 12/14/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832559757
Principal investigator 1 PFIZER INC. $2,054.80 12/07/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832560579
Principal investigator 1 PFIZER INC. $2,067.00 12/07/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832560587
Principal investigator 1 PFIZER INC. $54,514.95 11/30/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832658939
Principal investigator 1 PFIZER INC. $32,493.20 11/30/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832804363
Principal investigator 1 PFIZER INC. $3,691.78 11/16/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832658949
Principal investigator 1 PFIZER INC. $6,821.80 11/16/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832696879
Principal investigator 1 PFIZER INC. $9,870.80 11/16/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832758531
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $898.00 11/16/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251545
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $798.00 11/16/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251575
Principal investigator 1 PFIZER INC. $11,919.00 11/09/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832766131
Principal investigator 1 PFIZER INC. $27,560.20 11/09/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832888283
Principal investigator 1 PFIZER INC. $10,820.00 11/02/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832658729
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,160.40 11/02/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251407
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $399.00 11/02/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251561
Principal investigator 1 PFIZER INC. $14,297.00 10/29/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832768529
Principal investigator 1 PFIZER INC. $44,947.00 10/26/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832917309
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $898.00 10/14/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251539
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $798.00 10/14/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251569
Principal investigator 1 PFIZER INC. $10,820.00 10/01/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832708165
Principal investigator 1 PFIZER INC. $10,820.00 10/01/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832876045
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,347.00 09/28/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251555
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $449.00 09/22/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251549
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $798.00 09/22/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251579
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,572.80 09/14/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251341
Principal investigator 1 PFIZER INC. $113.80 09/13/2021 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832587905
Principal investigator 1 PFIZER INC. $229.25 09/07/2021 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832587915
Principal investigator 1 PFIZER INC. $2,751.00 08/18/2021 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832587897
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,694.00 07/27/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251551
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $399.00 07/27/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251581
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $733.35 07/27/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251595
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,347.00 07/16/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251543
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $399.00 07/16/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251571
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,796.00 07/07/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251535
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,596.00 07/07/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251565
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $880.02 07/07/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251587
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $5,793.00 07/06/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153665
Principal investigator 1 Sagent Pharmaceuticals, Inc. $8,274.00 07/01/2021 Non-covered Recipient Entity
EZY MEDICAL RESEARCH PAID BY ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421421
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $440.01 06/24/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251591
Principal investigator 1 Sagent Pharmaceuticals, Inc. $2,944.00 06/03/2021 Non-covered Recipient Entity
EZY MEDICAL RESEARCH PAID BY ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421461
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,796.00 06/02/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251533
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,596.00 06/02/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251559
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $586.68 06/02/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
CONNected Electronic Inhalers Asthma Control Trial 2 ("CONNECT 2"), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study of Standard of Care Treatment Versus the eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 806251585
Recipient Eli Lilly and Company $140.50 05/25/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) No dispute reported 06/30/2026 819444679
Principal investigator 1 Sagent Pharmaceuticals, Inc. $8,441.00 05/06/2021 Non-covered Recipient Entity
EZY MEDICAL RESEARCH PAID BY ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421479
Principal investigator 1 Sagent Pharmaceuticals, Inc. $3,500.00 04/22/2021 Non-covered Recipient Entity
EZY MEDICAL RESEARCH PAID BY ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421513
Principal investigator 1 Sagent Pharmaceuticals, Inc. $29,440.00 03/17/2021 Non-covered Recipient Entity
EZY MEDICAL RESEARCH PAID BY ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421531
Principal investigator 1 Sagent Pharmaceuticals, Inc. $950.00 03/11/2021 Non-covered Recipient Entity
EZY MEDICAL RESEARCH PAID BY ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421545
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $583.00 02/26/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153519
Recipient Eli Lilly and Company $1,513.83 02/23/2021 Covered Recipient Physician A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE No dispute reported 06/30/2026 819444489
Principal investigator 1 Sagent Pharmaceuticals, Inc. $280.00 02/10/2021 Non-covered Recipient Entity
EZY MEDICAL RESEARCH PAID BY ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421557
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,895.00 01/28/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789152835
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $583.00 01/28/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153029
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $583.00 01/28/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153205
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $583.00 01/28/2021 Non-covered Recipient Entity
Coral Research Clinic Corp
BAY94-8862 ph 3 conventional in diabetic nephropathy No dispute reported 06/30/2026 789153369
Principal investigator 1 Sagent Pharmaceuticals, Inc. $500.00 01/27/2021 Non-covered Recipient Entity
EZY MEDICAL RESEARCH PAID BY ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421577
Principal investigator 1 Avanir Pharmaceuticals, Inc. $19,593.75 01/22/2021 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
15-AVP-786-303 No dispute reported 06/30/2026 807075375
Principal investigator 1 Avanir Pharmaceuticals, Inc. $5,287.50 01/15/2021 Non-covered Recipient Entity
CORAL RESEARCH CLINIC CORP
15-AVP-786-303 No dispute reported 06/30/2026 807075643
Principal investigator 1 Sagent Pharmaceuticals, Inc. $280.00 01/11/2021 Non-covered Recipient Entity
ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808420995
Principal investigator 5 Sagent Pharmaceuticals, Inc. $500.00 01/07/2021 Non-covered Recipient Entity
ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421005
Principal investigator 2 Sagent Pharmaceuticals, Inc. $500.00 01/07/2021 Non-covered Recipient Entity
ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421013
Principal investigator 1 Sagent Pharmaceuticals, Inc. $500.00 01/07/2021 Non-covered Recipient Entity
ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421021
Principal investigator 1 Sagent Pharmaceuticals, Inc. $500.00 01/07/2021 Non-covered Recipient Entity
ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421030
Principal investigator 4 Sagent Pharmaceuticals, Inc. $280.00 01/07/2021 Non-covered Recipient Entity
ELIAS RESEARCH
CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) No dispute reported 06/30/2026 808421039